Cellastra
Company Details
Status: Private
Employees: 1-10
Location:
San Francisco, California, United States of America
Type:
sample
Technology:
sample
sample
sample
sample
About: Cellastra Inc., a developer of disruptive gene therapies, is a private biotech company based in the San Francisco Financial District. It was founded and managed by proven industry executives with a track record of execution.
Cellastra’s mission is to develop Disruptive, First or Best in Class Gene Therapies.
Cellastra Proprietary Technology - Gene Vector- Anti-scarring peptide:
Cellastra is developing viral gene vector-mediated intervention to address an area of great unmet medical needs in scarless wound healing after surgery and respiratory infections:
1. Surgery: Prevent excessive dermal scarring, e.g., after breast augmentation surgery, and C section.
2. Respiratory Infections: Prevent an excessive immune response, tissue damage, and scarring/fibrosis in high-risk patient groups with respiratory infections such as COVID-19 (coronavirus disease 2019) and RSV (respiratory syncytial virus).
Scarless wound healing can be achieved by using a gene vector encoding for endogenous continuous production of the anti-scarring peptides at the site of injury. Thus, two gene vectors are planned for development (Cellexa applied under the skin after surgery and Virexa inhaled into the lungs in COVID-19 and other respiratory infections). The development of these vectors is built and expands upon a foundation of scientific proof of concept data of the anti-scarring peptide ensereptide.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Cellastra | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.